The funding round was led by Newable Private Investing, the Development Bank of Wales, and angel investors.
"Jellyfish represent a source of ‘next generation’ collagen with diverse application potential, including for research in the medical, biotech and pharmaceutical markets,"
The funding will enable Bio-Images Drug Delivery to expand its manufacturing capacity and grow its team across two sites.
"OralogiK is a truly exciting technology that could transform the lives of many patients and this funding will accelerate its route to market. More than that, by partnering with Archangels, BDD can access its network of sector experts and ensure that we can fully capitalise on the potential of OralogiK"
Astia Angels and Wheatsheaf Group have backed the genomic analytics firm in its latest funding round.
"We have developed innovative analytics and AI capabilities that enable a new generation of precision medicine and precision agriculture solutions. The ability to deliver combinatorial, multi-omic analysis at scale is a critical missing piece in realising the benefits of the genomics, IOT and AI revolutions. This investment will enable us to scale our business to address the significant global opportunities in these high-growth markets."